Vimarsana
Biggest News Aggregation in the World

Long Term Extension News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Long Term Extension. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Long Term Extension Today - Breaking & Trending Today

New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year - Vimarsana News

New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year

Published: March 9, 2024

/PRNewswire/ -- Johnson & Johnson today announced the first data from FRONTIER 2, the long-term extension of the Phase 2b FRONTIER 1 clinical trial evaluating...

Source: prnewswire.com
Related Topics:
United StatesPrnewswire JohnsonLaura FerrisLloyd MillerCraig StoltzProtagonist Therapeutics IncUniversity Of PittsburghExchange CommissionJanssen Biotech IncAmerican Academy Of DermatologyNone Of Janssen Research DevelopmentNational Psoriasis FoundationJanssen Research DevelopmentEveryday HealthAmerican AcademyPsoriasis AreaSeverity IndexGlobal AssessmentNew England JournalProtagonist TherapeuticsJanssen BiotechVice PresidentImmunodermatology Disease Area LeaderInnovative MedicinePrivate Securities Litigation Reform Act
New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year - Vimarsana News

New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year

Published: March 9, 2024

Johnson & Johnson today announced the first data from FRONTIER 2, the long-term extension of the Phase 2b FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only...

Source: lelezard.com
Related Topics:
United StatesCraig StoltzPrnewswire JohnsonLloyd MillerLaura FerrisJanssen Research DevelopmentJanssen Biotech IncEveryday HealthAmerican Academy Of DermatologyUniversity Of PittsburghExchange CommissionNational Psoriasis FoundationNone Of Janssen Research DevelopmentProtagonist Therapeutics IncAmerican AcademyPsoriasis AreaSeverity IndexGlobal AssessmentNew England JournalProtagonist TherapeuticsJanssen BiotechVice PresidentImmunodermatology Disease Area LeaderInnovative MedicinePrivate Securities Litigation Reform Act
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting -October 19, 2023 at 07:31 am EDT - Vimarsana News

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting -October 19, 2023 at 07:31 am EDT

Published: October 19, 2023

Late-breaking Phase 1b data assesses the clinical outcomes of reducing tau in patients with early-stage Alzheimer’s diseaseAdditional late-breaking presentations from the CLARITY AD study explore...

Source: marketscreener.com
Related Topics:
United StatesUnited KingdomStatesprescribing InformationforChuck TrianoPriya SinghalJack CoxEisai Co LtdExchange CommissionAlzheimer AssociationDrug AdministrationHead Of Development At BiogenBiogen IncNovel Subcutaneous AdministrationLate Breaking PhaseClinical TrialsPresentations IncludeEarly AlzheimerLong Term OutcomesPredictive BiomarkersPlacebo Controlled PeriodLong Term ExtensionTopline ResultsSlower Clinical ProgressionAducanumab Treated PatientsBecame Amyloid
Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023 - Vimarsana News

Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023

Published: August 21, 2023

New analyses, including late-breaking data and presentations on CAMZYOS® and Eliquis® , reaffirm the company's steadfast dedication to tackling cardiovascular diseases ...

Source: marketscreener.com
Related Topics:
United KingdomSouth KoreaGreat BritainRoland ChenBristol Myers SquibbMaksabedian HernandezPfizer Alliance TheHead Of Cardiovascular Neuroscience DevelopmentGlobal Drug DevelopmentEuropean UnionPfizer AllianceExchange CommissionEuropean Society Of CardiologyYork Heart AssociationEuropean SocietyBristol Myers Squibb Pfizer AllianceSenior Vice PresidentNeuroscience DevelopmentGlobal DrugLong Term ExtensionLong Term Extension StudyNew York Heart AssociationRisk EvaluationMitigation StrategyInteractions Leading
Mining Stock News - Nicola Mining Inc. (TSXV: NIM) and Blue Lagoon Resources Inc. Sign Long Term Extension to Gold and Silver Profit Share Agreement with Blue Lagoon - Vimarsana News

Mining Stock News - Nicola Mining Inc. (TSXV: NIM) and Blue Lagoon Resources Inc. Sign Long Term Extension to Gold and Silver Profit Share Agreement with Blue Lagoon

Published: May 17, 2023

Mining Stock News - Nicola Mining Inc. (TSXV: NIM) and Blue Lagoon Resources Inc. Sign Long Term Extension to Gold and Silver Profit Share Agreement with Blue Lagoon

Source: investorideas.com
Related Topics:
British ColumbiaDome MountainProvince Of British ColumbiaUnited KingdomPeter EspigNicola Mining IncNational InstrumentRegulation Services ProviderNewswire Nicola Mining IncBlue Lagoon Resources IncVenture ExchangeTeck Resources LtdCompany Or NicolaNewsfile Corp InvestorideasNewsfile CorpNicola MiningBlue Lagoon ResourcesOriginal AgreementAmending AgreementBlue LagoonMerritt MillMineral ProjectsFrankfurt ExchangesMilling Profit Share AgreementsNew Craigmont Project